There’s significant excitement around the potential of PARP inhibitors in the currently established indication of ovarian cancer, but the best is probably yet to come with expansion into other cancers, according to a biopharma advisory firm. This class of drugs is also expected to trigger M&A, putting the spotlight on firms like Tesaro and Clovis Oncology.
Poly (ADP-ribose) polymerase (PARP) inhibitors are expected to bring about a paradigm shift in the treatment of solid tumors and M&A activity around this promising class of drugs may well be corollary, indicates a report by ProGrow Pharma Partners, an Indian life sciences advisory firm.
ProGrow notes how the PARP market opportunity in the approved indication of ovarian cancer is large but with certain firms...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
